Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD

References

• Masarone M, Federico A, Abenavoli L, et al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014;9:126–33
   PubMedGoogle Scholar
• Nobili V, Alkhouri N, Alisi A, et al. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015;169:170–6
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD. A perspective on metabolic syndrome and nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2015;13:258–8
   Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617–49
   PubMed Web of Science ®Google Scholar
• Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361–79
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–55
   PubMed Web of Science ®Google Scholar
• Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol 2015;62:S65–75
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–23
   PubMed Web of Science ®Google Scholar
• Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014;147:754–64
   PubMed Web of Science ®Google Scholar
• Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013;58:1218–29
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641–9
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Grimaldi C, et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes 2014;9:e99–102
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538–44
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47–64
   PubMed Web of Science ®Google Scholar
• Fintini D, Chinali M, Cafiero G, et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 2014;24:72–4
   PubMed Web of Science ®Google Scholar
• Pacifico L, Di Martino M, De Merulis A, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014;59:461–70
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341–50
   PubMed Web of Science ®Google Scholar
• VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 2015;62:773–83
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680
   PubMed Web of Science ®Google Scholar
• Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014;98:216–21
   PubMed Web of Science ®Google Scholar
• Day CP, James OFW. Steatohepatitis: a tale of two “hits”. Gastroenterology 1998;114:842–5
   PubMed Web of Science ®Google Scholar
• Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195–203
   PubMed Web of Science ®Google Scholar
• de Wit NJ, Afman LA, Mensink M, Müller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 2012;57:1370–3
   PubMed Web of Science ®Google Scholar
• Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:645–55
   PubMed Web of Science ®Google Scholar
• Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:637–44
   PubMed Web of Science ®Google Scholar
• Wree A, Broderick L, Canbay A, et al. From NAFLD to NASH to cirrhosis – new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627–36
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–5
   PubMed Web of Science ®Google Scholar
• Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209–17
   PubMed Web of Science ®Google Scholar
• Giudice EM, Grandone A, Cirillo G, et al. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One 2011;6:e27933
   PubMed Web of Science ®Google Scholar
• Davis JN, Lê KA, Walker RW, et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010;92:1522–7
   PubMed Web of Science ®Google Scholar
• Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013;19:210–15
   PubMedGoogle Scholar
• Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010;103:71–83
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:941–51
   Google Scholar
• Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829–38
   PubMed Web of Science ®Google Scholar
• Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007;10:142–8
   PubMed Web of Science ®Google Scholar
• Holt HB, Wild SH, Wood PJ, et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006;49:141–8
   PubMed Web of Science ®Google Scholar
• Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7:456–65
   PubMed Web of Science ®Google Scholar
• Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA 2004;101:15597–602
   PubMed Web of Science ®Google Scholar
• Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333–6
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805–20
   PubMed Web of Science ®Google Scholar
• Marra F, Gastaldelli A, Svegliati Baroni G, et al. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72–81
   PubMed Web of Science ®Google Scholar
• Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012;29:1098–107
   PubMed Web of Science ®Google Scholar
• Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:370–9
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009;87:679–95
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract 2010;2010:240365
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185–94
   PubMed Web of Science ®Google Scholar
• Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010;28:179–85
   PubMed Web of Science ®Google Scholar
• Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497–502
   PubMed Web of Science ®Google Scholar
• Dey A, Swaminathan K. Hyperglycemia-induced mitochondrial alterations in liver. Life Sci 2010;87:197–214
   PubMed Web of Science ®Google Scholar
• Pérez-Carreras M, Del Hoyo P, Martín MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999–1007
   PubMed Web of Science ®Google Scholar
• Calder PC. Mechanisms of action of (n − 3) fatty acids. J Nutr 2012;142:592S–9
   PubMed Web of Science ®Google Scholar
• Chapkin RS, Wang N, Fan YY, et al. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim Biophys Acta 2008;1778:466–71
   PubMed Web of Science ®Google Scholar
• Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003;126:1–27
   PubMed Web of Science ®Google Scholar
• Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 2013;33:231–48
   PubMed Web of Science ®Google Scholar
• Davis BC, Kris-Etherton PM. Achieving optimal essential fatty acid status in vegetarians: current knowledge and practical implications. Am J Clin Nutr 2003;78:640S–65
   PubMed Web of Science ®Google Scholar
• Araya J, Rodrigo R, Pettinelli P, et al. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring) 2010;18:1460–3
   PubMed Web of Science ®Google Scholar
• Merino DM, Johnston H, Clarke S, et al. Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults. Mol Genet Metab 2011;103:171–8
   PubMed Web of Science ®Google Scholar
• Schaeffer L, Gohlke H, Muller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006;15:1745–56
   PubMed Web of Science ®Google Scholar
• Shearer GC, Savinova OV, Harris WS. Fish oil – How does it reduce plasma triglycerides? Biochim Biophys Acta 2012;1821:843–51
   PubMed Web of Science ®Google Scholar
• Caviglia JM, Gayet C, Ota T, et al. Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res 2011;52:1636–51
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Yahagi N, Izumida Y, et al. Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem 2010;285:11681–91
   PubMed Web of Science ®Google Scholar
• Jump DB, Botolin D, Wang Y, et al. Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem Phys Lipids 2008;153:3–13
   PubMed Web of Science ®Google Scholar
• Khan SA, Ali A, Khan SA, et al. Unraveling the complex relationship triad between lipids, obesity, and inflammation. Mediators Inflamm 2014;2014:Article ID 502749
   Web of Science ®Google Scholar
• Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012;23:351–63
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87–91
   PubMed Web of Science ®Google Scholar
• Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–55
   PubMed Web of Science ®Google Scholar
• Calder PC, Ahluwalia N, Brouns F, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011;106:S5–78
   PubMed Web of Science ®Google Scholar
• Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002;45:805–12
   PubMed Web of Science ®Google Scholar
• Herder C, Illig T, Rathmann W, et al. Inflammation and type 2 diabetes: results from KORA Augsburg. Gesundheitswesen 2005;67:S115–21
   PubMed Web of Science ®Google Scholar
• Herder C, Peltonen M, Koenig W, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 2006;55:2340–6
   PubMed Web of Science ®Google Scholar
• de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97–105
   PubMed Web of Science ®Google Scholar
• Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345–53
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183–90
   PubMed Web of Science ®Google Scholar
• Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 2013;75:645–62
   PubMed Web of Science ®Google Scholar
• Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015;1851:469–84
   PubMed Web of Science ®Google Scholar
• Puschel GP, Jungermann K. Integration of function in the hepatic acinus: intercellular communication in neural and humoral control of liver metabolism. Prog Liver Dis 1994;12:19–46
   PubMedGoogle Scholar
• Enomoto N, Ikejima K, Yamashina S, et al. Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol 2000;279:G100–6
   PubMed Web of Science ®Google Scholar
• Henkel J, Frede K, Schanze N, et al. Stimulation of fat accumulation in hepatocytes by PGE2-dependent repression of hepatic lipolysis, b-oxidation and VLDL-synthesis. Lab Invest 2012;92:1597–606
   PubMed Web of Science ®Google Scholar
• Hespeling U, Jungermann K, Püschel GP. Feedback-inhibition of glucagon-stimulated glycogenolysis in hepatocyte/Kupffer cell cocultures by glucagon-elicited prostaglandin production in Kupffer cells. Hepatology 1995;22:1577–83
   PubMed Web of Science ®Google Scholar
• Henkel J, Neuschäfer-Rube F, Pathe-Neuschäfer-Rube A, Püschel GP. Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 2009;50:781–90
   PubMed Web of Science ®Google Scholar
• Fennekohl A, Lucas M, Püschel GP. Induction by interleukin 6 of G(s)-coupled prostaglandin E(2) receptors in rat hepatocytes mediating a prostaglandin E(2)-dependent inhibition of the hepatocyte’s acute phase response. Hepatology 2000;31:1128–34
   PubMed Web of Science ®Google Scholar
• Perez S, Aspichueta P, Ochoa B, Chico Y. The 2-series prostaglandins suppress VLDL secretion in an inflammatory condition-dependent manner in primary rat hepatocytes. Biochim Biophys Acta 2006;1761:160–71
   PubMed Web of Science ®Google Scholar
• Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010;1801:1260–73
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349–61
   PubMed Web of Science ®Google Scholar
• Rius B, Titos E, Morán-Salvador E, et al. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J 2014;28:836–48
   PubMed Web of Science ®Google Scholar
• Wanninger J1, Bauer S, Eisinger K, et al. Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol 2012;34:248–54
   Web of Science ®Google Scholar
• Jung TW, Hwang HJ, Hong HC, et al. Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells. Mol Cell Endocrinol 2014;391:30–40
   PubMed Web of Science ®Google Scholar
• Billiar T, Bankey P, Svingen B, et al. Fatty acid uptake and Kupffer cell function: fish oil alters eicosanoid and monokine production to endotoxin stimulation. Surgery 1988;104:343–9
   PubMed Web of Science ®Google Scholar
• Wong SW, Kwon WJ, Choi AM, et al. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009;284:27384–92
   PubMed Web of Science ®Google Scholar
• Zapata-Gonzalez F, Rueda F, Petriz J, et al. Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids. J Leukoc Biol 2008;84:1172–82
   PubMed Web of Science ®Google Scholar
• Lefils-Lacourtablaise J, Socorro M, Géloën A, et al. The eicosapentaenoic acid metabolite 15-deoxy-δ(12,14)-prostaglandin J3 increases adiponectin secretion by adipocytes partly via a PPARγ-dependent mechanism. PLoS One 2013;8:e63997
   PubMed Web of Science ®Google Scholar
• Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010;142:687–98
   PubMed Web of Science ®Google Scholar
• Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944–51
   PubMed Web of Science ®Google Scholar
• Chen R, Guo Q, Zhu WJ, et al. Therapeutic efficacy of (omega)-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease. World Chin J Digestol. 2008;16:2002–6
   Google Scholar
• Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 2010;61:792–802
   PubMed Web of Science ®Google Scholar
• Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008;14:6395–400
   PubMed Web of Science ®Google Scholar
• Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006;23:1143–51
   PubMed Web of Science ®Google Scholar
• Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008;40:194–9
   PubMedGoogle Scholar
• Sanyal AJ, Abdelmalek MF, Suzuki A, et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377–84
   PubMed Web of Science ®Google Scholar
• Burdge GC. Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot Essent Fatty Acids 2006;75:161–8
   PubMed Web of Science ®Google Scholar
• Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009;121:148–57
   PubMed Web of Science ®Google Scholar
• Molendi-Coste O, Legry V, Leclercq IA. Why and how meet n-3 PUFA dietary recommendations? Gastroenterol Res Pract 2011;2011:Article ID 364040
   Web of Science ®Google Scholar
• Kaur G, Cameron-Smith D, Garg M, Sinclair AJ. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog Lipid Res 2011;50:28–34
   PubMed Web of Science ®Google Scholar
• López-Vicario C, González-Périz A, Rius B, et al. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 2014;63:344–55
   PubMed Web of Science ®Google Scholar
• Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50:1827–38
   PubMed Web of Science ®Google Scholar
• Scorletti E, Bhatia L, McCormick KG, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemp Clin Trials 2014;37:301–11
   PubMed Web of Science ®Google Scholar
• Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the WELCOME* study. Hepatology 2014;60:1211–21
   PubMed Web of Science ®Google Scholar
• Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704–13
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846–54
   PubMed Web of Science ®Google Scholar
• Scorletti E, West AL, Bhatia L, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatology 2015. [Epub ahead of print]. doi:10.1016/j.jhep.2015.07.036
   PubMed Web of Science ®Google Scholar
• Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015;62:190–7
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747–57
   PubMed Web of Science ®Google Scholar
• Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190–200
   PubMed Web of Science ®Google Scholar
• Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012;35:2359–64
   PubMed Web of Science ®Google Scholar
• Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol 2014;60:1040–5
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447–55
   PubMed Web of Science ®Google Scholar
• Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010;376:540–50
   PubMed Web of Science ®Google Scholar
• McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 2007;27:715–28
   PubMed Web of Science ®Google Scholar
• Davidson MH, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol 2011;22:437–44
   PubMed Web of Science ®Google Scholar
• Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011;96:350–3
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013;23:1066–70
   PubMed Web of Science ®Google Scholar
• Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9:152–61
   PubMed Web of Science ®Google Scholar
• Nobili V, Carpino G, Alisi A, et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012;56:2142–53
   PubMed Web of Science ®Google Scholar
• Nobili V, Carpino G, Alisi A, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One 2014;9:e88005
   PubMed Web of Science ®Google Scholar
• Janczyk W, Socha P, Lebensztejn D, et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr 2013;13:85
   PubMed Web of Science ®Google Scholar
• Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr 2015;166:1358–63
   PubMed Web of Science ®Google Scholar
• Alkhouri N. The use of omega-3 fatty acids in nonalcoholic fatty liver disease: the end of the road or a new beginning? J Pediatr 2015;166:1335–7
   PubMed Web of Science ®Google Scholar
• Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003;166:85–93
   PubMed Web of Science ®Google Scholar
• Alisi A, Cianfarani S, Manco M, et al. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 2012;44:29–40
   PubMed Web of Science ®Google Scholar
• Nobili V, Bedogni G, Donati B, et al. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 2013;16:957–60
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148–55
   PubMed Web of Science ®Google Scholar